Details of Viral Vaccine
This Viral vaccine card gives comprehensive information about each vaccine.
| Detailed Information | |
|---|---|
| ID | 10246 |
| Vaccine Name | SII B.1.617.2 |
| Disease Name | COVID-19 |
| Disease Classification | Respiratory |
| Virus Name | SARS-CoV-2 virus |
| Nucleic Acid Content | positive-sense, single-stranded RNA |
| Vaccine Type | Protein subunit |
| Vaccine Status | Phase 2 |
| Manufacturer | Novavax Inc. |
| Year of Manufacturing | 2021 |
| Manufacturing Country | Australia |
| Age | 18 - 64 years |
| Dosage | 2 doses 21 days apart |
| Administration Route | Intramuscular |
| Adjuvant | Matrix-M1 |
| Target Strain | Bivalent SII vaccine containing antigen for both the ancestral strain and B.1.351 (Beta) variant of SARS-CoV-2 (SII Bivalent) |
| Description | NA |
| Approving Organisation | NA |
| Collaborating Organisation | NA |
| Other Countries | NA |
| Trade Name | NA |
| PMID | NA |
| Clinical Trial ID | NCT05029856 |
| Reference Link | https://clinicaltrials.gov/ct2/show/NCT05029856 |
| Additional Links | NA |